Stroke Therapy Targeted at Platelet Glycoprotein Still Considered Promising Despite Negative Trial

Expanding Options for Hereditary Transthyretin Amyloidosis with Polyneuropathy

Benefit from Early Treatment of Secondary Progressive MS Appears Persistent Up to 7 Years

STR1VE-EU: Gene Replacement Therapy in Symptomatic Spinal Muscular Atrophy Is Associated with Substantial Benefit

Gene Therapy for Spinal Muscular Atrophy Effective as First- or Second-line Therapy

Head-to-Head Trial Shows Large Clinical Advantage for CGRP Monoclonal Antibody in Migraine Prophylaxis

Efficacy of Spinal Muscular Atrophy Therapies Depends on Early Initiation

Spinal Muscular Atrophy Remains Controlled in a Phase 3 Study with New Gene Therapy: SPR1NT Trial

Cognitive Function as an Endpoint in Secondary Progressive Multiple Sclerosis

Targeted Agent Found Better than Immunomodulator as First-Line Strategy for Relapsing Multiple Sclerosis

Extended Protection from Disability and Cognitive Dysfunction
Seen in Active SPMS

Relapsing-Remitting Multiple Sclerosis and High-efficacy Therapies